ki-67_in_recurrent_vestibular_schwannoma

Ki-67 in recurrent vestibular schwannoma

see also MIB Index in recurrent vestibular schwannoma.

Some researchers have analyzed the Ki-67 proliferative index of vestibular schwannoma 1) 2) 3) 4) 5) 6) 7) 8) 9).

Charabi et al., were the first to describe the growth rate of VSs as expressed by Ki-67 in relation to symptom duration, reported that tumors with a high proliferative status showed a short preoperative symptom duration, while tumors with a low proliferative status had a long symptom duration. Subsequently, other authors assumed that tumor growth was positively associated with a higher proliferative status as expressed by Ki-67 10) 11).

The Ki-67 index may be useful for determining the probability of regrowth of vestibular schwannomas when only partial removal is accomplished 12).

In patients with a Ki-67 index greater than 3 per cent, more frequent clinical examination and radiological follow up are recommended 13).

References

1)
Bedavanija A, Brieger J, Lehr HA, et al. Association of proliferative activity and size in acoustic neuroma: implications for timing of surgery. J Neurosurg 2003; 98: 807–811.
2)
Light JP, Roland JT, Jr, Fishman A, et al. Atypical and low-grade malignant vestibular schwannomas: clinical implications of proliferative activity. Otol Neurotol 2001; 22: 922–927.
3)
Lesser TH, Janzer RC, Kleihues P, et al. Clinical growth rate of acoustic schwannomas: correlation with the growth fraction as defined by the monoclonal antibody ki-67. Skull Base Surg 1991; 1: 11–15.
4)
Cafer S, Bayramoglu I, Uzum N, et al. Expression and clinical significance of Ki-67, oestrogen and progesterone receptors in acoustic neuroma. J Laryngol Otol 2008; 122: 125–127.
5)
O’Reilly BF, Kishore A, Crowther JA, et al. Correlation of growth factor receptor expression with clinical growth in vestibular schwannomas. Otol Neurotol 2004; 25: 791–796.
6) , 10)
Charabi S, Engel P, Charabi B, et al. Growth of vestibular schwannomas: in situ model employing the monoclonal antibody Ki-67 and DNA flow cytometry. Am J Otol 1996; 17: 301–306.
7) , 11)
Charabi S, Engel P, Jacobsen GK, et al. Growth rate of acoustic neuroma expressed by Ki-67 nuclear antigen versus symptom duration. Ann Otol Rhinol Laryngol 1993; 102: 805–809.
8)
Yokoyama M, Matsuda M, Nakasu S, et al. Clinical significance of Ki-67 staining index in acoustic neurinoma. Neurol Med Chir (Tokyo) 1996; 36: 698–702.
9)
Niemczyk K, Vaneecloo FM, Lecomte MH, et al. Correlation between Ki-67 index and some clinical aspects of acoustic neuromas (vestibular schwannomas). Otolaryngol Head Neck Surg 2000; 123: 779–783.
12)
Iannella G, de Vincentiis M, Di Gioia C, Carletti R, Pasquariello B, Manno A, Angeletti D, Savastano E, Magliulo G. Subtotal resection of vestibular schwannoma: Evaluation with Ki-67 measurement, magnetic resonance imaging, and long-term observation. J Int Med Res. 2017 Jun;45(3):1061-1073. doi: 10.1177/0300060516686873. Epub 2017 Apr 27. PubMed PMID: 28447494; PubMed Central PMCID: PMC5536425.
13)
Prueter J, Norvell D, Backous D. Ki-67 index as a predictor of vestibular schwannoma regrowth or recurrence. J Laryngol Otol. 2019 Mar;133(3):205-207. doi: 10.1017/S0022215119000549. PubMed PMID: 30983565.
  • ki-67_in_recurrent_vestibular_schwannoma.txt
  • Last modified: 2024/06/07 02:50
  • by 127.0.0.1